Navigation Links
Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion
Date:7/10/2014

Montreal, QC (PRWEB) July 10, 2014

EvoDerma’s NOOME Anti-Aging Motion has been upgraded for more comfort and convenience. This rejuvenating device now comes with a second treatment cup to help prevent and smooth skin damage that develops over time.

The new cup is thinner on the edges for a softer contact with the skin. This design works to target rough, thin and uneven surfaces on the face, neck and décolleté. Choose to use the original firm cup for a stimulating treatment on areas such as the cheeks and neck, or opt for the new soft cup, which delicately works on areas such as the cheekbones and forehead. Users can switch between both to make the most of the cup’s benefits and discover the best combination for their skin type and comfort.

NOOME incorporates professional non-invasive sub-dermal therapy (NIST) to deliver rejuvenating results for a youthful appearance. With the option of two treatment cups, NOOME is now more convenient and effortless in smoothening and brightening the complexion.

NOOME Anti-Aging Motion and its new bonus addition will be available starting Thursday, July 10, 2014. Visit http://evoderma.com or call 1-855-EVO-DERM (1-855-386-3376) for more information.

About

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Introducing a New, Easy Way for Industrial Businesses to Join the Online Conversation
2. Introducing version 4.0 of ezColony™ - Transgenic Animal Colony Management Software
3. iLuv Introducing NFC & Qi-Certified Technology to Bluetooth Speaker Lineup at 2013 CES
4. Impact with Martin Sheen Introducing Audiences to the Next Generation of Environmental Custodians
5. Express Diagnostics Introducing New Products and Expanded Catalog of Drug Tests at the 2013 AACC Clinical Lab Expo
6. Introducing a Personal Injury Chiropractor in Tampa Florida That is Utilizing the Latest Treatment Technology in the Industry, Courtesy of Elan Wellness Center
7. Introducing the BioProcess International Online Poster Hall 2014
8. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
11. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Cord Blood Corporation (NYSE: CO ) ("CCBC," the "Company," ... provider of cord blood collection, laboratory testing, hematopoietic stem cell ... Special Committee of the Company,s board of directors (the "Special ... ) Limited as its independent financial advisor, Cleary ... United States legal counsel and Maples & Calder ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 German-based Moenninghoff ... United States distributor for the Moenninghoff product line ... “I am pleased to announce that the R.M. Hoffman ... For our firm, founded in 1916, this is a ... Hoffman is the kind of professional distributor we need ...
(Date:6/1/2015)... South Korea , June 1, 2015 ... Inc. (GCBT) kicked off construction today on its biopharmaceutical ... Saint-Laurent Campus. The CA$315 million project represents one of ... Canada in the biopharmaceutical industry, giving place ... and albumin manufacturing plant in Canada ...
(Date:6/1/2015)... HANOVER, N.J. , June 1, 2015 /PRNewswire/ ... II clinical study of CTL019, an investigational chimeric ... its potential in the treatment of specific types ... study conducted by the University of Pennsylvania,s Perelman ... or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) ...
Breaking Biology Technology:China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... , BIRMINGHAM, Ala. , Jan. 19 ... when it comes to cholesterol. According to a new study, a ... — can be labeled "bad cholesterol." The landmark study Genetic ... published in the New England Journal Of Medicine provides ...
... , , NEW HAVEN, Conn. , ... today that it has appointed Dr. Richard J. Carroll ... Research. , Dr. Carroll brings to HistoRx over 20 years ... diagnostic, pharmaceutical and medical device industries. Before joining HistoRx in ...
... CITY, China , Jan. 19 /PRNewswire-Asia-FirstCall/ -- ... fully,integrated and highly innovative biopharmaceutical company engaged in the,research and ... today announced financial results for the second quarter ended, November ... 2010 Highlights, -- Total revenue increased by ...
Cached Biology Technology:New Study: Lp(a) Joins LDL as Heart Disease Risk Factor 2New Study: Lp(a) Joins LDL as Heart Disease Risk Factor 3HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 2HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 3Sinobiopharma Announces Second Quarter 2010 Financial Results 2Sinobiopharma Announces Second Quarter 2010 Financial Results 3Sinobiopharma Announces Second Quarter 2010 Financial Results 4
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
(Date:4/27/2015)... 2015  For more than four decades, AUVSI,s ... the premier worldwide event for the unmanned land, sea, ... event for any local, national, or trade news organization ... markets and current applications of unmanned technologies. The conference ... $48 billion industry, and how it will soon impact ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... 18, 2009 Pharmaceuticals and personal care products (PPCPs) ... reach surface waters or groundwater when these materials ... the high flow conditions created by land application ... of solutes in soil macropores may be too ...
... radiation therapy treatment damages a patient,s healthy tissue as ... destroy, making the treatment especially invasive and often causing ... will enable a far more precise and accurate treatment ... the radiation beam. Real-time image-guided radiotherapy, combining radiation ...
... available in French . , Montreal, May ... known to humans, and its abuse has become widespread since ... we know rather little about its effects on the human ... latest article by Dr. Marco Leyton, of the Montreal Neurological ...
Cached Biology News:Simulating pharmaceutical and personal care product transport 2Cocaine: Perceived as a reward by the brain? 2
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
...
Antibody Diluent for IHC 125 ml...
Biology Products: